Targeting epoxides for organ damage in hypertension

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 4, 2010, Pages 329-335

  Imig, John D ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

epoxyeicosatrienoic acids; hypertension; kidney; soluble epoxide hydrolase; vascular

Indexed keywords

11,12 EPOXYICOSATRIENOIC ACID STIMULATING AGENT; 12 (3 ADAMANTAN 1 YL UREIDO)DODECANOIC ACID; 14,15 EPOXYICOSATRIENOIC ACID STIMULATING AGENT; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTIHYPERTENSIVE AGENT; AR 9281; EPOXIDE; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE INHIBITOR; EPOXYICOSATRIENOIC ACID; INSULIN; UNCLASSIFIED DRUG;

BLOOD PRESSURE REGULATION; BRAIN DAMAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; DRUG MECHANISM; ENZYME INHIBITION; HEART INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY INJURY; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; EICOSANOIDS; EPOXIDE HYDROLASES; EPOXY COMPOUNDS; HUMANS; HYPERTENSION; MOLECULAR TARGETED THERAPY;

EID: 77958468395     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181e96e0c     Document Type: Review

References (79)

1. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004; 351:1709-1711.
2. Ribeiro JD, Toro AA, Baracat EC. Antileukotrienes in the treatment of asthma and allergic rhinitis. J Pediatr (Rio J). 2006;82:S213-S221.
3. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002;82:131-185.
4. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009;8:794-805.
5. Spector AA, Fang X, Snyder GD, et al. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res. 2004;43:55-90.
6. Jacobson HR, Corona S, Capdevila JH, et al. Effects of epoxyeicosa-trienoic acids on ion transport in the rabbit cortical collecting tubule. In: Braquet P, Garay RP, Frohlich JC, et al, eds. Prostaglandins, and Membrane Ion Transport. New York: Raven Press; 1985:311-318.
7. Sakairi Y, Jacobson HR, Noland TD, et al. 5,6-EET inhibits ion transport in collecting duct by stimulating endogenous prostaglandin synthesis. Am J Physiol. 1995;268:F931-F939.
8. Campbell WB, Gebremedhin D, Pratt PF, et al. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 1996;78:415-423.
9. Archer SL, Gragasin FS, Wu X, et al. Endothelium-derived hyper-polarizing factor in human internal mammary artery is 11,12-epoxyei-cosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. Circulation. 2003;107:769-776.
10. Fisslthaler B, Popp R, Kiss L, et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature. 1999;401:493-497.
11. Capdevila JH, Falck JR, Imig JD. Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. Kidney Int. 2007;72:683-689.
12. Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol. 2005;289: F496-F503.
13. Imig JD, Zhao X, Zaharis CZ, et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension. 2005;46:975-981.
14. King LM, Gainer JV, David GL, et al. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet Genomics. 2005;15:7-13.
15. Imig JD. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc Drug Rev. 2006;24:169-188.
16. Heizer ML, McKinney JS, Ellis EF. 14,15-Epoxyeicosatrienoic acid inhibits platelet aggregation in mouse cerebral arterioles. Stroke. 1991;22: 1389-1393.
17. Krotz F, Riexinger T, Buerkle MA, et al. Membrane-potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler Thromb Vasc Biol. 2004;24:595-600.
18. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999;285: 1276-1279.
19. Davis BB, Thompson DA, Howard LL, et al. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA. 2002;99:2222-2227.
20. Fleming I. Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat. 2007;82:60-67.
21. Yang S, Wei S, Pozzi A, et al. The arachidonic acid epoxygenase is a component of the signaling mechanisms responsible for VEGF-stimulated angiogenesis. Arch Biochem Biophys. 2009;489:82-91.
22. Potente M, Fisslthaler B, Busse R, et al. 11,12-Epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by down-regulating p27Kip1. J Biol Chem. 2003;278:29619-29625.
23. Sun J, Sui X, Bradbury JA, et al. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res. 2002;90:1020-1027.
24. Athirakul K, Bradbury JA, Graves JP, et al. Increased blood pressure in mice lacking cytochrome P450 2J5. Faseb J. 2008;22:4096-4108.
25. Gauthier KM, Falck JR, Reddy LM, et al. 14,15-EET analogs: characterization of structural requirements for agonist and antagonist activity in bovine coronary arteries. Pharmacol Res. 2004;49:515-524.
26. Sudhahar V, Shaw S, Imig JD. Epoxyeicosatrienoic acid analogs and vascular function. Curr Med Chem. 2010;17:1181-1190.
27. Proctor KG, Falck JR, Capdevila J. Intestinal vasodilation by epoxyei-cosatrienoic acids: arachidonic acid metabolites produced by a cytochrome P450 monooxygenase. Circ Res. 1987;60:50-59.
28. Imig JD, Navar LG, Roman RJ, et al. Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol. 1996;7:2364-2370.
29. Larsen BT, Miura H, Hatoum OA, et al. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol. 2006;290:H491-H499.
30. Gebremedhin D, Ma YH, Falck JR, et al. Mechanism of action of cerebral epoxyeicosatrienoic acids on cerebral arterial smooth muscle. Am J Physiol. 1992;263:H519-H525.
31. Dimitropoulou C, West L, Field MB, et al. Protein phosphatase 2A and Ca2+-activated K+ channels contribute to 11,12-epoxyeicosatrienoic acid analog mediated mesenteric arterial relaxation. Prostaglandins Other Lipid Mediat. 2007;83:50-61.
32. Falck JR, Reddy LM, Reddy YK, et al. 11,12-epoxyeicosatrienoic acid (11,12-EET): structural determinants for inhibition of TNF-alpha-in-duced VCAM-1 expression. Bioorg Med Chem Lett. 2003;13: 4011-4014.
33. Schmelzer KR, Kubala L, Newman JW, et al. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA. 2005;102:9772-9777.
34. Potente M, Michaelis UR, Fisslthaler B, et al. Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1. J Biol Chem. 2002; 277:15671-15676.
35. Yan G, Chen S, You B, et al. Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epox-yeicosatrienoic acids. Cardiovasc Res. 2008;78:308-314.
36. Pozzi A, Macias-Perez I, Abair T, et al. Characterization of 5,6-and 8,9-epoxyeicosatrienoic acids (5,6-and 8,9-EET) as potent in vivo angiogenic lipids. J Biol Chem. 2005;280:27138-27146.
37. Fitzpatrick FA, Ennis MD, Baze ME, et al. Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J Biol Chem. 1986;261:15334-15338.
38. Cambell WB, Fleming I. Epoxyeicosatrienoic acids and endothelium- dependent responses. Pflugers Arch Eur J Physiol. 2010;459:881-895.
39. Graier WF, Simecek S, Sturek M. Cytochrome P450 mono-oxygenase-regulated signaling of Ca2+ entry in human and bovine endothelial cells. J Physiol. 1995;482:259-274.
40. Hoebel BG, Kostner GM, Graier WF. Activation of microsomal cytochrome P450 mono-oxygenase by Ca2+ store depletion and its contribution to Ca2+ entry in porcine aortic endothelial cells. Br J Pharmacol. 1997;121:1579-1588.
41. Mombouli JV, Holzmann S, Kostner GM, et al. Potentiation of Ca2+ signaling in endothelial cells by 11,12-epoxyeicosatrienoic acid. J Cardiovasc Pharmacol. 1999;33:779-784.
42. Weston AH, Félétou M, Vanhoutte PM, et al. Bradykinin-induced, endothelium-dependent responses in porcine coronary arteries: involvement of potassium channel activation and epoxyeicosatrienoic acids. Br J Pharmacol. 2005;145:775-784.
43. Vriens J, Owsianik G, Fisslthaler B, et al. Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ Res. 2005;97:908-915.
44. + channels. Microcirculation. 2008;15:137-150.
45. Imig JD, Inscho EW, Deichmann PC, et al. Afferent arteriolar vasodilation to the sulfonimide analog of 11, 12-epoxyeicosatrienoic acid involves protein kinase A. Hypertension. 1999;33:408-413.
46. Yu Z, Xu F, Huse LM, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res. 2000;87:992-998.
47. Hwang SH, Tsai HJ, Liu JY, et al. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007;50:3825-3840.
48. Loch D, Hoey A, Morisseau C, et al. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys. 2007;47:87-98.
49. Jung O, Brandes RP, Kim IH, et al. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension. 2005;45:759-765.
50. Fornage M, Hinojos CA, Nurowska BW, et al. Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension. 2002;40:485-490.
51. Olearczyk JJ, Quigley JE, Mitchell BC, et al. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin Sci (Lond). 2009;116:61-70.
52. Simpkins AN, Rudic RD, Schreihofer DA, et al. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol. 2009;174:2086-2095.
53. Luria A, Weldon SM, Kabcenell AK, et al. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem. 2007;282:2891-2898.
54. Manhiani M, Quigley JE, Knight SF, et al. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol. 2009;297:F740-F448.
55. Sinal CJ, Miyata M, Tohkin M, et al. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem. 2000;275:40504-40510.
56. Certikova Chabova V, Walkowska A, Kompanowska-Jezierska E, et al. Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin Sci (Lond). 2010;118:617-632.
57. Zhao X, Yamamoto T, Newman JW, et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol. 2004;15:1244-1253.
58. Ai D, Pang W, Li N, et al. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci USA. 2009;106:564-569.
59. Gross GJ, Gauthier KM, Moore J, et al. Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol. 2008;294:H2838-H2844.
60. Merkel MJ, Liu L, Cao Z, et al. Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling. Am J Physiol Heart Circ Physiol. 2010;298:H679-H687.
61. Motoki A, Merkel MJ, Packwood WH, et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am J Physiol Heart Circ Physiol. 2008;295: H2128-H2134.
62. Seubert JM, Sinal CJ, Graves J, et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res. 2006; 99:442-450.
63. Xu D, Li N, He Y, et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA. 2006;103: 18733-18738.
64. Zhang W, Otsuka T, Sugo N, et al. Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. Stroke. 2008;39:2073-2078.
65. Simpkins AN, Rudic RD, Roy S, et al. Soluble epoxide hydrolase inhibition modulates vascular remodeling. Am J Physiol Heart Circ Physiol. 2010;298:H795-H806.
66. Shen HC, Ding FX, Wang S, et al. Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement. J Med Chem. 2009;52:5009-5012.
67. Marino JP Jr. Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery. Curr Top Med Chem. 2009;9:452-463.
68. Sodhi K, Inoue K, Gotlinger KH, et al. Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice. J Pharmacol Exp Ther. 2009;331:906-916.
69. Imig JD, Falck JR.Compositions and methods for the treatment of renal and cardiovascular disease. US Patent #7,550,617, 2009.
70. Falck JR, Kodela R, Manne R, et al. 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) Surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition. J Med Chem. 2009;52:5069-5075.
71. Falck JR, Krishna UM, Reddy YK, et al. Comparison of vasodilatory properties of 14,15-EET analogs: structural requirements for dilation. Am J Physiol Heart Circ Physiol. 2003;284:H337-H349.
72. Gauthier KM, Jagadeesh SG, Falck JR, et al. 14,15-epoxyeicosa-5(Z)-enoic- mSI: a 14,15-and 5,6-EET antagonist in bovine coronary arteries. Hypertension. 2003;42:555-561.
73. Gauthier KM, Deeter C, Krishna UM, et al. 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res. 2002;90:1028-1036.
74. Imig JD, Zhao X, Falck JR, et al. Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid. J Hypertens. 2001;19:983-992.
75. Yang W, Holmes BB, Gopal VR, et al. Characterization of 14,15-epoxyeicosatrienoyl-sulfonamides as 14,15-epoxyeicosatrienoic acid agonists: use for studies of metabolism and ligand binding. J Pharmacol Exp Ther. 2007;321:1023-1031.
76. Shaw S, Shrestha B, Nithripatikom K, et al. LC-MS measurement of the epoxyeicosatrienoic acid mimetic EET-8-ZE-D in rat serum. F A S E B J. 2009; 23:1019.13. Available at: http://www.fasebj.org/cgi/content/meeting-abstract/23/ 1-MeetingAbstracts/1019.13. Accessed March 17, 2010.
77. Schmelzer KR, Inceoglu B, Kubala L, et al. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA. 2006;103:13646-13651.
78. Terashvili M, Tseng LF, Wu HE, et al. Antinociception produced by 14,15-epoxyeicosatrienoic acid is mediated by the activation of beta-endorphin and met-enkephalin in the rat ventrolateral periaqueductal gray. J Pharmacol Exp Ther. 2008;326:614-622.
79. Inceoglu B, Jinks SL, Schmelzer KR, et al. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci. 2006;79: 2311-2319.